Sanofi to Double Flu-Vaccine Production
Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility.
Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility. According to the company, this manufacturing plant will more than double its production capacity in the US. The new 14,000-square-foot facility, which cost $150 million to build, is expected to start functioning in late 2008 or early 2009, after the FDA licenses the facility.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
